Drawing for CHIPSCREEN

USPTO serial 98935309

CHIPSCREEN

Reviewed by CopyMark Law Group

Reg. 7944971Status 700Registered
Filing date
Status date
Registration date
Sep 16, 2025
Examiner
HINES, REGINA C
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with CHIPSCREEN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Nazly Aileen Bayramoglu

Nazly Aileen Bayramoglu Bayramoglu Law Offices LLC1540 West Warm Springs Road Suite 100Henderson, NV 89014United States

Goods and services

ClassDescriptionStatusFirst use
005Medicines for human purposes, namely, the medicines for the treatment of lymph cancer, leukemia, multiple myeloma, myelodysplasia syndrome, cystadenocarcinoma, breast cancer, lung cancer, liver cancer, intestinal cancer, stomach cancer, nasopharyngeal cancer, skin cancer, and diabetes; antiviral medicine preparations; chemical preparations for pharmaceutical or medical purposes, namely, for lymph cancer, leukemia, multiple myeloma, myelodysplasia syndrome, cystadenocarcinoma, breast cancer, lung cancer, liver cancer, intestinal cancer, stomach cancer, nasopharyngeal cancer, skin cancer, diabetes; capsules sold empty for pharmaceuticals; dietetic substances, namely, syrups for making meal replacement beverages adapted for medical use; medicines for veterinary purposes, namely, veterinary preparations for pigs, cattle and sheep in the nature of vaccines, bacteriological preparationsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 22, 2026EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Jul 22, 2026TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jul 22, 2026ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 22, 2026REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Sep 16, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Sep 16, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 29, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jul 29, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 23, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jun 24, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 14, 2025DOCKASSIGNED TO EXAMINER—
Jun 3, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 3, 2025NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance